To Show Nonobviousness, Commercial Success Must Be "Direct Result" Of Patented Subject Matter
Client Alert | 1 min read | 11.07.08
In In re DBC (No. 2008-1120; November 3, 2008), the Federal Circuit affirms a final decision of the United States Patent and Trademark Office Board of Patent Appeals and Interferences ("the Board"), which affirmed the examiner's rejection of all pending claims under 35 U.S.C. § 103 as obvious during ex parte reexamination of U.S. Patent No. 6,730,333. The Federal Circuit holds that: (1) DBC waived the argument that the decision of the Board must be vacated because two of the administrative patent judges on the panel were appointed unconstitutionally by failing to raise it before the Board; (2) contrary to the assertion of DBC, the Board's prima facie case of obviousness is based upon a substantial new question of patentability, and the reference newly cited during the ex parte reexamination, together with the other references cited, is substantial evidence fully supporting the Board's finding of a prima facie case of obviousness; and (3) the evidence of commercial success presented by DBC was insufficient to overcome the prima facie case of obviousness of the claimed subject matter.
Regarding commercial success, the Court explained, "We have held on a number of occasions that evidence of commercial success alone is not sufficient to demonstrate nonobviousness of a claimed invention. Rather, the proponent must offer proof 'that the sales were a direct result of the unique characteristics of the claimed invention - as opposed to other economic and commercial factors unrelated to the quality of the patented subject matter.'"
Contacts
Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 2 min read | 03.27.26
CMS Releases PY 2020 RADV Audit Methods and Instructions: Key Takeaways for Health Plans
Client Alert | 4 min read | 03.25.26
NAIC Intensifies AI Regulatory Focus: What Health Insurance Payors Need to Know
Client Alert | 11 min read | 03.25.26
White House National AI Policy Framework Calls for Preempting State Laws, Protecting Children

